A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.

about

New treatment options for inflammatory bowel diseases.

P2860

Q52647462-68C0DCBE-A507-47C4-87F0-B46F704AA0A4

P2860

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.

Item

http://www.wikidata.org/entity/Q38749257

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A safety assessment of biologi ...... n inflammatory bowel diseases.

@en

type

Item

label

A safety assessment of biologi ...... n inflammatory bowel diseases.

@en

prefLabel

A safety assessment of biologi ...... n inflammatory bowel diseases.

@en

P1476

A safety assessment of biologi ...... n inflammatory bowel diseases.

@en

P2093

Barbara Deleenheer

http://www.w3.org/2001/XMLSchema#string

Bram Verstockt

http://www.w3.org/2001/XMLSchema#string

Marc Ferrante

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis.

Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.

P304

809-821

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1338273

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Séverine Vermeire

Gert Van Assche

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28573876

http://www.w3.org/2001/XMLSchema#string

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.

about

P2860

P2860

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698